spacer
home > ict > autumn 2018 > streamlining start-ups
PUBLICATIONS
International Clinical Trials

Streamlining Start-Ups

New life sciences industry research reveals significant momentum towards streamlining clinical systems and processes over the past year. More than 300 clinical operations professionals from around the globe were surveyed in an annual unified clinical operations survey to track the industry’s progress in improving clinical operations. Nearly all clinical leaders (99%) recognise the need to unify their clinical operating environments, and most (87%) have plans in place to get there.

Better Visibility and Faster Trial Execution

The widespread move to unify clinical environments is being driven by application and process silos that have resulted from the steady adoption of function-specific clinical technologies over the past decade. Stand-alone eClinical applications, including electronic data capture, electronic trial master files (eTMFs), randomisation and trial supply management, and clinical trial management systems (CTMSs) are now the norm. Newer, purpose-built applications, such as study start-up, are gaining traction (1).

Faced with a landscape of disparate systems and processes, over three quarters (77%) of those surveyed find better visibility across their clinical trial processes a top driver for unifying clinical applications. Other primary drivers include faster study execution (67%), improved study quality (62%), and increased productivity (51%).

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

 You must be a member of the site to make a comment.
spacer
Rik Van Mol is Vice President of R&D Strategy at Veeva Systems, responsible for the Veeva Vault R&D suite of applications in Europe. Rik has nearly 20 years of experience in business/IT consulting and has regulated content management in the life sciences sector. His experience has been built on assisting clients through complex transformational programmes across the life sciences value chain, including clinical, regulatory, and manufacturing/supply chain areas for some of the world’s largest companies.
spacer
Rik Van Mol
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Teknova completes FDA notification for room temperature-stable viral transport medium

Hollister, CA – 16 Dec 2020. Teknova, a leading manufacturer of cell culture media and supplements, purification buffers, and molecular biology reagents, has completed the process of FDA notification for its Active Viral Transport Medium (ATM). ATM is a room temperature-stable version of Teknova’s CDC formulation Viral Transport Medium (VTM) and is manufactured under GMP conditions in compliance with ISO 13485 standards.
More info >>

White Papers
 

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement